Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 12/2017

01-12-2017 | Letter

Europe has to step up its efforts to produce innovative and safe diabetes technology

Authors: Miriam Cnop, Tomasz Klupa, Nikolaos Tentolouris, Anna Novials, Rémy Burcelin, Mischa van Eimeren

Published in: Diabetologia | Issue 12/2017

Login to get access

Excerpt

To the Editor: There is an ongoing (legislative) debate on medical devices and in vitro diagnostics at the European Union (EU) level that will influence the future of diabetes technology and, in particular, the safety and innovation of new devices. …
Literature
1.
Thabit H, Hovorka R (2016) Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. Expert Opin Drug Deliv 13:389–400CrossRefPubMed
2.
Guilhem I, Balkau B, Lecordier F et al (2009) Insulin pump failures are still frequent: a prospective study over 6 years from 2001 to 2007. Diabetologia 52:2662–2664CrossRefPubMed
3.
Guenego A, Bouzille G, Breitel S et al (2016) Insulin pump failures: has there been an improvement? Update of a prospective observational study. Diabetes Technol Ther 18:820–824CrossRefPubMed
4.
5.
Heinemann L, Fleming GA, Petrie JR, Holl RW, Bergenstal RM, Peters AL (2015) Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia 58:862–870CrossRefPubMed
6.
7.
Metadata
Title
Europe has to step up its efforts to produce innovative and safe diabetes technology
Authors
Miriam Cnop
Tomasz Klupa
Nikolaos Tentolouris
Anna Novials
Rémy Burcelin
Mischa van Eimeren
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 12/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4455-4

Other articles of this Issue 12/2017

Diabetologia 12/2017 Go to the issue

Article

The MST3/STK24 kinase mediates impaired fasting blood glucose after a high-fat diet

Letter

Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]

Article

KLF10 transcription factor regulates hepatic glucose metabolism in mice

Research Letter

South Asian men have lower expression of IFN signalling genes in white adipose tissue and skeletal muscle compared with white men

Article

Application of white blood cell SPECT/CT to predict remission after a 6 or 12 week course of antibiotic treatment for diabetic foot osteomyelitis

Commentary

Osteomyelitis of the foot: non-surgical management, SPECT/CT scanning and minimising the duration of antibiotic use
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits